An interventional study of SLN identification using technetium-99m and SLN intra-operatory identification with radioguided surgery in Invasive Breast Carcinoma, Sentinel Lymph Node Biopsy (SLNB) and Neoadjuvant Chemotherapy, sponsored by European Institute of Oncology. Recruiting at 1 site in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by European Institute of Oncology · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Breast Neoplasms by European Institute of Oncology — 40 open to participants now, 48 under way, 2 of them phase 3. Breast Neoplasms · European Institute of Oncology.
Among the 64 studies in Breast Neoplasms by European Institute of Oncology, this one is the 25th largest by planned enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2025, is one of 24 with no phase, reaches primary completion later than 45 of the 47 other live ones, and was the 59th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →40 of the 64 studies in Breast Neoplasms by European Institute of Oncology are open now, in 1 country. Recruiting first, the newest first:
European Institute of Oncology · Sites in Italy
Ages 18+ · Women only
European Institute of Oncology · Sites in Italy
Ages 18+
European Institute of Oncology · Sites in Italy
Ages 18+
European Institute of Oncology · Sites in Italy
Ages 18+
European Institute of Oncology · Sites in Italy
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is close to the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 94 across the 37 interventional studies, 200 across the 27 observational. Of the 16 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
European Institute of Oncology is the lead sponsor of 186 studies on the registry; 118 are open to participants now.
12 of the studies in Breast Neoplasms by European Institute of Oncology that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06611514Phase 3European Institute of OncologyEffect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer | 2027-01-01 |
| NCT06690840European Institute of OncologyAtezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients | 2026-12-15 |
| NCT06706557European Institute of OncologyAnalysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer | 2026-12-31 |
| NCT06706570European Institute of OncologyPIK3CA Mutational Status Assessment | 2026-12-31 |
| NCT06762483European Institute of OncologyIntegrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients, | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 64 studies in Breast Neoplasms by European Institute of Oncology, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will prospectively determine the feasibility and oncological safety of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NACT) in inflammatory breast cancer patients traditionally considered ineligible for SLNB due to locally advanced cancer with skin/chest wall involvement (cT4d) and heavy nodal burden at presentation (cN1/N2). This study will also assess the identification rate of sentinel lymph-node (SLN) (using single tracer mapping) after NACT in this patient population. Finally, the study will determine the long-term outcome of such cohort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with SLN visualization.
Procedure: SLN identification using technetium-99m
Patients with no pre-surgery SLN visualization and intra-surgery SLN identification.
Procedure: SLN intra-operatory identification with radioguided surgery
Patients with no pre-surgery SLN visualization and no intra-surgery SLN identification.
Procedure: Axillary Limph Node Dissection (ALND)
SLN Biopsy after pre-surgery positive SLN visualization.
SLN biopsy after no pre-surgery SLN visualization using technetium-99m and intra-surgery SLN identification.
Axillary Limph Node Dissection (ALND) after no pre-surgery SLN visualization using technetium-99m and no intra-surgery SLN identification.
intraoperative SLN identification rate.
Evaluation of the feasibility of SLNB in a selected cohort of IBC patients operated who responded to systemic NACT in the axillary nodes, achieving complete clinical response (ycN0). The feasibility of SLNB, defined as the intraoperative SLN identification rate, will be calculated as the proportion of patients with successfully identified intraoperative SLNs among the enrolled patients.
Time frame: 3 Months
Disease-free survival (DFS)
DFS will be defined as the time from surgery to loco-regional recurrence, metastasis, other primary non-breast carcinomas, or death, whichever occurs first.
Time frame: 5 years.
Distant recurrence-free survival (DRFS)
DRFS will be defined as the time from surgery to distant recurrence or death from any cause, whichever occurs first.
Time frame: 5 years
Breast cancer-specific survival (BCSS)
BCSS will be defined as the time from surgery to death due to breast cancer.
Time frame: 5 years
Overall survival (OS)
OS will be defined as the time from surgery to death from any cause.
Time frame: 5 years
Started Dec 2025 (actual). Primary completion is estimated for Jul 2030, 55 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 55 months is above that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
European Institute of Oncology →